Company: Cipla Ltd.

Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Ambrisentan tablets,
April 30, 2019, 12:41 p.m.

The USFDA has classified both the recalls as a Class-II recall
April 28, 2019, 12:50 p.m.

Drug major Cipla Ltd. said its South African subsidiary will acquire 30 % stake in connected healthcare firm Brandmed Pty Ltd for an upfront cash consideration of ZAR 65 million (nearly Rs 32 crore).
April 17, 2019, 6:01 a.m.

Drug major Cipla on Tuesday said its South Africa-based subsidiary will acquire 30 per cent stake in the connected healthcare firm Brandmed (Pty) Ltd
April 16, 2019, 10:34 p.m.

Cipla and Pulmatrix inks agreement for the co-development and commercialisation of Pulmazole.As per the pact, Cipla will make an upfront payment of $22 million to Pulmatrix in exchange for assignment of all rights for Pulmazole in relation to pulmonary indications
April 15, 2019, 9:06 p.m.

In an effort to address patients with small airway respiratory diseases, drugmaker Cipla has rolled out its extra-fine particle beclomethasone-formot
April 12, 2019, 2:29 p.m.

Niraj Shah and Yash Upadhyaya share technical insights on which direction Cipla’s stock may move next.
April 8, 2019, 9:05 a.m.

Cipla on Thursday said that it has received the Establishment Inspection Report for its Goa plant from the United States Food and Drug Administration,
April 4, 2019, 10:03 p.m.

Drug major Cipla on Sunday said it has received eight good manufacturing practices (GMP) observations from the US health regulator for its Kurkumbh f
April 1, 2019, 10:19 a.m.

The observations issued after a product specific pre-approval (PAI) and Good Manufacturing Practices (GMP) inspection of Kurkumbh plant from March 11, 2019, to March 20, 2019.
April 1, 2019, 8:22 a.m.